Boston Scientific (BSX) Change in Receivables (2020 - 2026)

Boston Scientific (BSX) has 7 years of Change in Receivables data on file, last reported at $117.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 9.35% year-over-year to $117.0 million; the trailing twelve-month figure through Mar 2026 stood at $279.0 million (down 18.9% YoY), and the FY2025 full-year result was $269.0 million, down 23.36% from the prior year.
• Change in Receivables advanced to $117.0 million in Q1 2026, from $98.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $117.0 million in Q1 2026 to a low of $3.0 million in Q3 2023.
• A 5-year average of $70.3 million and a median of $75.0 million in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables plunged 78.57% in 2023 and jumped 1000.0% in 2024, its largest moves.
• Tracing BSX's Change in Receivables over 5 years: stood at $44.0 million in 2022, then soared by 68.18% to $74.0 million in 2023, then grew by 21.62% to $90.0 million in 2024, then advanced by 8.89% to $98.0 million in 2025, then increased by 19.39% to $117.0 million in 2026.
• Business Quant data shows BSX's Change in Receivables at $117.0 million in Q1 2026, $98.0 million in Q4 2025, and $32.0 million in Q3 2025.